167.86
2.00%
-3.42
After Hours:
167.86
Repligen Corp. stock is currently priced at $167.86, with a 24-hour trading volume of 534.82K.
It has seen a -2.00% decreased in the last 24 hours and a -15.24% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $170.3 pivot point. If it approaches the $166.4 support level, significant changes may occur.
Previous Close:
$171.28
Open:
$169.82
24h Volume:
534.82K
Market Cap:
$9.37B
Revenue:
$638.76M
Net Income/Loss:
$41.58M
P/E Ratio:
82.69
EPS:
2.03
Net Cash Flow:
$74.93M
1W Performance:
+4.27%
1M Performance:
-15.24%
6M Performance:
+20.09%
1Y Performance:
-0.20%
Repligen Corp. Stock (RGEN) Company Profile
Name
Repligen Corp.
Sector
Industry
Phone
781-250-0111
Address
Building 1, Suite 100 41 Seyon Street, Waltham, MA
Repligen Corp. Stock (RGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
Jul-20-23 | Initiated | Wells Fargo | Overweight |
Jul-05-23 | Resumed | JP Morgan | Overweight |
Mar-28-23 | Initiated | The Benchmark Company | Buy |
Dec-14-22 | Initiated | Deutsche Bank | Hold |
Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
Jul-20-22 | Initiated | UBS | Buy |
Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
May-07-20 | Reiterated | H.C. Wainwright | Buy |
Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
Nov-15-19 | Initiated | Stifel | Buy |
Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
Oct-15-19 | Initiated | SVB Leerink | Outperform |
Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
Aug-23-19 | Resumed | Stephens | Overweight |
Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
Dec-17-18 | Upgrade | CL King | Neutral → Buy |
Nov-12-18 | Downgrade | CL King | Buy → Neutral |
Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
Dec-08-17 | Initiated | Citigroup | Buy |
Dec-05-17 | Initiated | JP Morgan | Overweight |
Nov-13-17 | Initiated | CL King | Buy |
Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
Jul-21-17 | Initiated | William Blair | Outperform |
Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp. Stock (RGEN) Latest News
Repligen to Report First Quarter 2024 Financial Results
GlobeNewswire Inc.
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Benzinga
Repligen Appoints Maggie A. Pax to Board of Directors
GlobeNewswire Inc.
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Zacks Investment Research
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
Zacks Investment Research
What's Going On With Life Science-Focused Repligen Stock Today?
Benzinga
Repligen Corp. Stock (RGEN) Financials Data
Repligen Corp. (RGEN) Revenue 2024
RGEN reported a revenue (TTM) of $638.76 million for the quarter ending December 31, 2023, a -20.31% decline year-over-year.
Repligen Corp. (RGEN) Net Income 2024
RGEN net income (TTM) was $41.58 million for the quarter ending December 31, 2023, a -77.64% decrease year-over-year.
Repligen Corp. (RGEN) Cash Flow 2024
RGEN recorded a free cash flow (TTM) of $74.93 million for the quarter ending December 31, 2023, a +93.43% increase year-over-year.
Repligen Corp. (RGEN) Earnings per Share 2024
RGEN earnings per share (TTM) was $0.72 for the quarter ending December 31, 2023, a -77.85% decline year-over-year.
Repligen Corp. Stock (RGEN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
KURIYEL RALF | Senior VP, R&D |
Mar 11 '24 |
Option Exercise |
86.10 |
1,271 |
109,433 |
27,777 |
KURIYEL RALF | Senior VP, R&D |
Mar 11 '24 |
Sale |
193.73 |
3,517 |
681,348 |
24,260 |
Hunt Anthony | Chief Executive Officer |
Mar 08 '24 |
Option Exercise |
16.55 |
1 |
17 |
201,956 |
Hunt Anthony | Chief Executive Officer |
Mar 08 '24 |
Sale |
197.44 |
16,707 |
3,298,632 |
185,249 |
DAWES KAREN A | Director |
Feb 27 '24 |
Option Exercise |
42.07 |
4,626 |
194,616 |
88,367 |
DAWES KAREN A | Director |
Feb 27 '24 |
Sale |
193.35 |
1,000 |
193,350 |
87,367 |
Bylund James | Chief Operating Officer |
Feb 23 '24 |
Option Exercise |
94.33 |
940 |
88,670 |
18,508 |
Bylund James | Chief Operating Officer |
Feb 23 '24 |
Sale |
198.08 |
4,373 |
866,204 |
14,135 |
Gebski Christine | See Remarks |
Nov 10 '23 |
Sale |
147.13 |
3,788 |
557,328 |
28,787 |
DAWES KAREN A | Director |
Aug 29 '23 |
Option Exercise |
18.12 |
7,392 |
133,943 |
84,591 |
About Repligen Corp.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Cap:
|
Volume (24h):